📰 Solid Tumors News
Page 35 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
April 20, 2023
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting ... | April 20, 2023
April 20, 2023
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment settingBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its pr...
April 20, 2023
University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.
April 18, 2023
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at... | April 18, 2023
April 18, 2023
Kura Oncology, Inc. (NASDAQ:KURA – Get Rating)’s share price was down 5.3% during mid-day trading on Tuesday . The company traded as low as $10.88 and last traded at $10.90. Approximately 135,098 shares traded hands during trading, a decline of 79% from the average daily volume of 632,237 shares. The stock had previously closed at […]
April 18, 2023
This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w
April 18, 2023
Should You Buy or Sell Kura Oncology Stock? Get The Latest KURA Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
April 17, 2023
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a... | April 17, 2023
April 17, 2023
Should You Buy or Sell Kura Oncology Stock? Get The Latest KURA Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
April 13, 2023
13.04.2023 - SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) - Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and ...